Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141689 | 0.89 | NPSR1 (0.46) | NPSR1ATMTDP1L3MBTL1PTGIR | |
| SCHEMBL6905225 | 0.82 | KMT2A (0.46) | NPSR1ATMTDP1L3MBTL1KMT2A | |
| SCHEMBL4458935 | 0.82 | NPSR1 (0.47) | NPSR1ATMTDP1L3MBTL1KMT2A | |
| SCHEMBL398536 | 0.79 | NPSR1 (0.44) | NPSR1ATMTDP1L3MBTL1PTGIR | |
| SCHEMBL3424139 | 0.78 | SMN1; SMN2 (0.44) | NPSR1ATMTDP1L3MBTL1KMT2A | |
| SCHEMBL402771 | 0.76 | NPSR1 (0.41) | NPSR1ATMTDP1L3MBTL1PTGIR | |
| SCHEMBL17674048 | 0.72 | DHFR (0.42) | KMT2AHTTMEN1 | |
| SCHEMBL4657473 | 0.72 | ALDH1A1 (0.58) | NPSR1L3MBTL1KMT2AALDH1A1POLB | |
| SCHEMBL10510080 | 0.71 | NPC1 (0.34) | KMT2AHTTRAB9ANPC1KDM4E | |
| SCHEMBL2404029 | 0.70 | NPSR1 (0.45) | NPSR1ATMTDP1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2134677-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2134677-A2 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2111401-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008079968-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079972-A2 | 4-{4- [ ({3-TERT-BUTYL-1- [3- (HYDROXYMETHYL) PHENYL] - 1H- PYRAZOL- 5 -YL } CARBAMOYL) -AMIN O] -3-CHLOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | TP53, DOT1L, VHL | NPSR1 4479/4885ATM 2450/4885TDP1 1199/4885 |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | TP53, MGMT, VHL | NPSR1 4492/4885ATM 867/4885TDP1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.